Advertisement

Topics

Latest "Boehringer Ingelheim Corporation" News Stories - Page: 5

19:15 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Boehringer Ingelheim Corporation" found in our extensive news archives from over 250 global news sources.

More Information about Boehringer Ingelheim Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Boehringer Ingelheim Corporation for you to read. Along with our medical data and news we also list Boehringer Ingelheim Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Boehringer Ingelheim Corporation Companies for you to search.

Showing "Boehringer Ingelheim Corporation" News Articles 101–125 of 984

Relevant

STAT Plus: AbbVie and Boehringer Ingelheim are locked in patent litigation over Humira and lower-cost biosimilar alternatives. https://buff.ly/2SQBlBk 

STAT Plus: AbbVie and Boehringer Ingelheim are locked in patent litigation over Humira and lower-cost biosimilar alternatives. https://buff.ly/2SQBlBk 


STAT Plus: Boehringer Ingelheim's litigation holds the potential for peeling back the curtain on the patent thicket strategy. https://buff.ly/2RBYnHY 

STAT Plus: Boehringer Ingelheim's litigation holds the potential for peeling back the curtain on the patent thicket strategy. https://buff.ly/2RBYnHY 

Boehringer Ingelheim, Eli Lilly's DPP-4 inhibitor Tradjenta hits main goal of cardiovascular outcome study https://www.firstwordpharma.com/node/1625221  $LLY

Boehringer Ingelheim, Eli Lilly's DPP-4 inhibitor Tradjenta hits main goal of cardiovascular outcome study https://www.firstwordpharma.com/node/1625221  $LLY


Dedicated to research for animals.

Dr Joachim Hasenmaier, Corporate Board Divisions Animal Health and Consumer Healthcare at Boehringer Ingelheim

Boehringer Ingelheim: CMOs, Biosimilars, R&D

Wolfgang Baiker, Corporate Divisions, operations and biopharmaceuticals, discusses the 3 pillars of their biopharmaceutical strategy.

Boehringer Ingelheim exercises option to buy ViraTherapeutics, boosting viral-based approach to treating cancer https://www.firstwordpharma.com/node/1590857 

Boehringer Ingelheim exercises option to buy ViraTherapeutics, boosting viral-based approach to treating cancer https://www.firstwordpharma.com/node/1590857 

Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million... http://dlvr.it/QrKD6l pic.twitter.com/f9enVT1lxo

Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million... http://dlvr.it/QrKD6l  pic.twitter.com/f9enVT1lxo

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

Boehringer Ingelheim Expands Biomarker-driven Oncology Programs Alliance Enhances Epizyme’s Leadership in Oncology Epigenetics Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) today announced a new global collaboration focused on the research, development and commercialization of novel small molecule inhibitors d...

Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders

Stevenage, UK – 18 January 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced that the first milestone has successfully been achieved under Autifony’s option agreement with Boehringer Ingelheim. As announced previously, Boehringer Ingelheim acquired an exc...

Boehringer Ingelheim Is Getting Bets In Early In IO Space

The head of the German family-owned firm's venture fund tells Scrip that investing very early in promising start-ups gives Boehringer...   

Boehringer Ingelheim Is Getting Bets In Early In I-O Space

The head of the German family-owned firm's venture fund tells Scrip that investing very early in promising start-ups gives Boehringer...   

Boehringer $LLY ; CAROLINA® CVOT of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-announce-the-carolina-cardiovascular-outcome-trial-of-tradjenta-

Boehringer $LLY ; CAROLINA® CVOT of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-announce-the-carolina-cardiovascular-outcome-trial-of-tradjenta-met-its-primary-endpoint-of-non-inferiority-compared-with-glimepiride-300795420.html …

Vargatef Plus Docetaxel Could be an Option After Failure of Immunotherapy in Lung Cancer

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. ...

It's all about innovation!

Allan Hillgrove, Corporate Board Division Pharma Marketing and Sales at Boehringer Ingelheim explains to PharmaVentures' CEO, Fintan Walton how they are going to take the organisation back into profit through 2015 and beyond.

Is change is the new normal?

Andreas Neumann, head of HR at Boehringer Ingelheim discusses the impact their recent deal with Sanofi has had on Human Resources, and how to address the company’s strategic needs from a people perspective.

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics ViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim’s Discovery Research organization, maintaining its innovative biotech heritage and close connections to the Medical Unive...

Boehringer Ingelheim expands biologics manufacturing in China

Upgrade at the Oasis facility includes GMP operations of 2x 2.000L single-use bioreactor manufacturing lines

Boehringer wins access to Humira documents as Janssen’s Remicade is relisted in Quebec

Boehringer Ingelheim is the only biosimilar manufacturer still challenging AbbVie’s Humira (adalimumab) patents in court, and has just won a legal battle to gain access to documents AbbVie has fought hard to keep private. Meanwhile, Janssen has had Remicade (infliximab) reinstated on Quebec’s List of Medications after a decision by the Minister of Health and Social Services to “delist” Rem...

Boehringer Ingelheim GmbH Strategic SWOT Analysis Review [Report Updated: 08082018] Prices from USD $125

Boehringer Ingelheim GmbH Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.This uptotheminute company report will help you to formulate strategies to drive your bu...

OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRPα antagonist BI 765063* under Development in Collaboration with Boehringer Ingelheim in Patients with Ad

First-in-class SIRPα checkpoint inhibitorDiscovered and validated on OSE's immune target discovery platform NANTES, France, March 05, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced authorization by the French National Agency for Medicines and Health Products Safety (ANSM) and by the Belgian Federal Agency for Medicines and Health Product...

Epizyme partners with BI on cancer therapeutics

Epizyme Inc. is collaborating with Boehringer Ingelheim GMBH to develop novel small molecule inhibitors for cancer.

Auftragsherstellung: AGC übernimmt Wirkstoff-Produktionsanlage von Boehringer Ingelheim in Spanien

Mit der Übernahme von MPC verfügt AGC über seinen ersten von der FDA registrierten Standort in Europa im Bereich Auftragsherstellung und -Entwicklung (CDMO) für synthetische Arzneimittel. Auf diese...

STAT Plus: Boehringer Ingelheim abandons biosimilar sales outside the U.S.

As drug makers scramble over the biosimilar market, one company has reportedly decided to focus exclusively on the U.S., a nascent, but particularly large opportunity for pharmaceutical companies.

Study Shows using Giotrif/Gilotrif Followed by Osimertinib Provides a Median of 27.6 Months of Chemotherapy-Free Time in Patients with NSCLC

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations, the most common mechanism...

Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies

Boehringer Ingelheim collaborates with Science 37 to accelerate the clinical development of new therapies worldwide Science 37’s technology enables patients to remotely participate in clinical studies, which enables increased patient diversity, study efficiency and speed, while decreasing patient burden Science 37...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks